BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Cell-free DNA (cfDNA) is evolving into a widely used prognostic and predictive biomarker,
particularly in oncology. However, its versatile clinical use precedes a profound …

Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis
of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive …

Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of
noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma …

Cell-free DNA (cfDNA) in human plasma is a class of biomarkers with many current and
potential future diagnostic applications. Recent studies have shown that cfDNA molecules …

Plasma cell-free DNA (cfDNA) are small molecules generated through a non-random
fragmentation procedure. Despite commendable translational values in cancer liquid biopsy …

Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode
of 166 bp. Data supporting this view has been mainly acquired through the analysis of …

Circulating DNA in plasma consists of short DNA fragments. The biological processes
generating such fragments are not well understood. DNASE1L3 is a secreted DNASE1-like …

Epigenetic mechanisms play instrumental roles in gene regulation during embryonic
development and disease progression. However, it is challenging to non-invasively monitor …